omeprazole has been researched along with Regurgitation, Gastric in 18 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Regurgitation, Gastric: GASTROESOPHAGEAL REFLUX wherein the retrograde flow passes through the UPPER ESOPHAGEAL SPHINCTER
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of domperidone in combination with omeprazole in the treatment of laryngopharyngeal reflux (LPR) compare to omeprazole alone." | 9.16 | Treatment of laryngopharyngeal reflux: a comparison between domperidone plus omeprazole and omeprazole alone. ( Hunchaisri, N, 2012) |
| "To evaluate the efficacy of domperidone in combination with omeprazole in the treatment of laryngopharyngeal reflux (LPR) compare to omeprazole alone." | 5.16 | Treatment of laryngopharyngeal reflux: a comparison between domperidone plus omeprazole and omeprazole alone. ( Hunchaisri, N, 2012) |
| "Six parameters of voice range profile (VRP) and five parameters of speech range profile were taken and analyzed from 60 dysphonic outpatient females with laryngopharyngeal reflux (LPR) diagnosed by reflux-related atypical and typical symptoms, videolaryngoscopic findings, upper gastrointestinal endoscopy, and positive response to empiric 3-month omeprazole treatment." | 3.75 | [Usefulness of assessment of voice capabilities in female patients with reflux-related dysphonia]. ( Adamonis, K; Siupsinskiene, N; Toohill, RJ, 2009) |
| " Our aim was to compare effectiveness of increased PPI dosing with laparoscopic magnetic sphincter augmentation (MSA) in patients with moderate-to-severe regurgitation despite once-daily PPI therapy." | 2.90 | Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. ( Abbas, G; Bell, R; Buckley, FP; Dunst, C; Gould, J; Hill, M; Jacobsen, G; Katz, P; Khaitan, L; Kothari, S; Lipham, J; Lister, D; Louie, B; Luketich, J; McDowell-Jacobs, L; Park, A; Reardon, P; Richards, W; Smith, C; Smith, CD; Williams, V; Woods, K, 2019) |
| " This work intends to evaluate once-daily, 40 mg omeprazole and once-nightly, 300 mg ranitidine (QD/QHS) dosing as an alternative regimen, and use this study's cohort to evaluate empiric regimens prescribed for LPR as compared to up-front testing with pH impedance multichannel intraluminal impedance (MII) with dual pH probes and high-resolution manometry (HRM) for potential cost minimization." | 1.46 | Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease. ( Carroll, TL; Dezube, A; Nahikian, K; Roth, DF; Werner, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 14 (77.78) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Pizzorni, N | 2 |
| Ambrogi, F | 1 |
| Eplite, A | 1 |
| Rama, S | 1 |
| Robotti, C | 2 |
| Lechien, J | 1 |
| Schindler, A | 2 |
| Carroll, TL | 2 |
| Werner, A | 1 |
| Nahikian, K | 1 |
| Dezube, A | 1 |
| Roth, DF | 1 |
| Anzić, SA | 1 |
| Turkalj, M | 1 |
| Župan, A | 1 |
| Labor, M | 1 |
| Plavec, D | 1 |
| Baudoin, T | 1 |
| Qi, ZW | 1 |
| Lu, HL | 1 |
| Zhang, J | 1 |
| Zhang, SJ | 1 |
| Bell, R | 1 |
| Lipham, J | 1 |
| Louie, B | 1 |
| Williams, V | 1 |
| Luketich, J | 1 |
| Hill, M | 1 |
| Richards, W | 1 |
| Dunst, C | 1 |
| Lister, D | 1 |
| McDowell-Jacobs, L | 1 |
| Reardon, P | 1 |
| Woods, K | 1 |
| Gould, J | 1 |
| Buckley, FP | 1 |
| Kothari, S | 1 |
| Khaitan, L | 1 |
| Smith, CD | 1 |
| Park, A | 1 |
| Smith, C | 1 |
| Jacobsen, G | 1 |
| Abbas, G | 1 |
| Katz, P | 1 |
| Mozzanica, F | 1 |
| Lechien, JR | 1 |
| Pirola, F | 1 |
| Mengucci, A | 1 |
| Dell'Era, A | 1 |
| Ottaviani, F | 1 |
| Angotoeva, IB | 1 |
| Muldasheva, AA | 1 |
| Dabirmoghaddam, P | 1 |
| Amali, A | 1 |
| Motiee Langroudi, M | 1 |
| Samavati Fard, MR | 1 |
| Hejazi, M | 1 |
| Sharifian Razavi, M | 1 |
| Li, J | 2 |
| Zhang, L | 1 |
| Zhang, C | 1 |
| Cheng, JY | 1 |
| Jeff Cheng, CF | 1 |
| Yadlapati, R | 1 |
| Pandolfino, JE | 1 |
| Lidder, AK | 1 |
| Shabeeb, N | 1 |
| Jaiyeola, DM | 1 |
| Adkins, C | 1 |
| Agrawal, N | 1 |
| Cooper, A | 1 |
| Price, CP | 1 |
| Ciolino, JD | 1 |
| Gawron, AJ | 1 |
| Smith, SS | 1 |
| Bove, M | 1 |
| Tan, BK | 1 |
| Siupsinskiene, N | 1 |
| Adamonis, K | 1 |
| Toohill, RJ | 1 |
| Szczesniak, MM | 1 |
| Williams, RB | 1 |
| Brake, HM | 1 |
| Maclean, JC | 1 |
| Cole, IE | 1 |
| Cook, IJ | 1 |
| Becker, S | 1 |
| Schmidt, C | 1 |
| Berghaus, A | 1 |
| Tschiesner, U | 1 |
| Olzowy, B | 1 |
| Reichel, O | 1 |
| Sana, S | 1 |
| Sana, M | 1 |
| Johnston, N | 1 |
| Mittal, SK | 1 |
| Ndraha, S | 1 |
| Hunchaisri, N | 1 |
| Fedore, LW | 1 |
| Aldahlawi, MM | 1 |
| Wang, XY | 1 |
| Ye, JY | 1 |
| Han, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis - a Randomized, Double Blind, Placebo Controlled Trial[NCT03086070] | Phase 4 | 60 participants (Actual) | Interventional | 2010-01-01 | Completed | ||
| The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease[NCT02505945] | Phase 4 | 152 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux[NCT03463395] | 0 participants (Actual) | Interventional | 2020-07-31 | Withdrawn (stopped due to Funding for this study has ended and we were unable to enroll any subjects) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary endpoint was the percent of patients in both treatment arms who achieved elimination of moderate-severe regurgitation at 6 months, as reported on the foregut symptom questionnaire. (NCT02505945)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Arm | 10 |
| Treatment Arm | 42 |
Successful Reduction at 6 months (≥50% reduction in total) Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) scores from Baseline PPI On medication GERD HRQL scores. (NCT02505945)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Arm | 7 |
| Treatment Arm | 38 |
10 trials available for omeprazole and Regurgitation, Gastric
| Article | Year |
|---|---|
Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial.
Topics: Alginates; Humans; Laryngopharyngeal Reflux; Magnesium; Omeprazole; Prospective Studies; Proton Pump | 2022 |
Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Method; Drug Administration Schedule; | 2018 |
[Effect of different course of omeprazole in the treatment of laryngopharyngeal reflux].
Topics: Capsules; Humans; Laryngopharyngeal Reflux; Omeprazole; Pepsin A; Proton Pump Inhibitors; Recurrence | 2018 |
Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial.
Topics: Adult; Aged; Cross-Over Studies; Esophageal pH Monitoring; Esophageal Sphincter, Lower; Female; Gast | 2019 |
The effect of N-acetyl cysteine on laryngopharyngeal reflux.
Topics: Acetylcysteine; Adult; Female; Humans; Laryngopharyngeal Reflux; Male; Middle Aged; Omeprazole; Plac | 2013 |
Linguistic Adaptation, Reliability, Validation, and Responsivity of the Chinese Version of Reflux Symptom Index.
Topics: China; Esophageal pH Monitoring; Hospitals, University; Humans; Language; Laryngopharyngeal Reflux; | 2016 |
Upregulation of the esophago-UES relaxation response: a possible pathophysiological mechanism in suspected reflux laryngitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Esophageal Sphincter, Upper; Esophagus; Female; Humans; Laryngophary | 2010 |
Combination of PPI with a prokinetic drug in gastroesophageal reflux disease.
Topics: Administration, Oral; Adult; Antiemetics; Domperidone; Double-Blind Method; Drug Synergism; Drug The | 2011 |
Treatment of laryngopharyngeal reflux: a comparison between domperidone plus omeprazole and omeprazole alone.
Topics: Anti-Ulcer Agents; Chi-Square Distribution; Domperidone; Dopamine Antagonists; Drug Therapy, Combina | 2012 |
[Clinical value of 24-hour pH monitoring in patients with laryngopharyngeal reflux disease].
Topics: Adult; Aged; Antacids; Esophageal pH Monitoring; Female; Humans; Laryngopharyngeal Reflux; Male; Mid | 2007 |
8 other studies available for omeprazole and Regurgitation, Gastric
| Article | Year |
|---|---|
Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease.
Topics: Algorithms; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Co | 2017 |
Vocal Tract Discomfort and Dysphonia in Patients Undergoing Empiric Therapeutic Trial with Proton Pump Inhibitor for Suspected Laryngopharyngeal Reflux.
Topics: Adult; Aged; Aged, 80 and over; Dysphonia; Female; Humans; Laryngopharyngeal Reflux; Male; Middle Ag | 2020 |
[Laryngopharyngeal reflux as a possible cause of adenoiditis in adult patients].
Topics: Adenoids; Adolescent; Adult; Enzyme Inhibitors; Female; Humans; Laryngopharyngeal Reflux; Male; Omep | 2013 |
Oropharyngeal pH Testing Does Not Predict Response to Proton Pump Inhibitor Therapy in Patients with Laryngeal Symptoms.
Topics: Adult; Chronic Disease; Cohort Studies; Cough; Deglutition Disorders; Female; Hoarseness; Humans; Hy | 2016 |
[Usefulness of assessment of voice capabilities in female patients with reflux-related dysphonia].
Topics: Adult; Anti-Ulcer Agents; Chi-Square Distribution; Dysphonia; Female; Humans; Informed Consent; Lary | 2009 |
Does laryngopharyngeal reflux cause intraoral burning sensations? A preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Burning Mouth Syndrome; Cohort Studies; Esophageal pH Monitoring; Fe | 2011 |
Hoarseness and chronic cough: would you suspect reflux?
Topics: Adult; Chronic Disease; Cough; Diagnosis, Differential; Drug Therapy, Combination; Female; Fundoplic | 2011 |
pH Impedance and high-resolution manometry in laryngopharyngeal reflux disease high-dose proton pump inhibitor failures.
Topics: Adult; Aged; Analysis of Variance; Esophageal pH Monitoring; Female; Humans; Laryngopharyngeal Reflu | 2012 |